Tandem Therapeutics is developing first-in-class peptide therapeutics that target and treat the extracellular matrix barrier.
Tandem Therapeutics has raised €152k across 1 funding round from 1 investor, most recently a round in Feb 2023. Based in Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-02-24 | Other | €152k |
| Venture Kick |
| View deal → |
